GH Research is trading 5.9% up at $26.84 as investors react to continued clinical and regulatory progress for its depression treatments.
- Shares are currently hovering near 52-week highs, rebounding from previous sector-wide weakness and post-earnings losses.
- Market enthusiasm remains high for the GH001 Phase 3 development path following positive trial data and recent FDA milestones.